[1] |
Ferlay J,Shin HR,Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
|
[2] |
中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版).临床肿瘤学杂志, 2011, 16(10): 929-946.
|
[3] |
Semela D,Dufour JF. Angiogenesis and hepatocellular carcinoma. J Hepatol, 2004, 41(5): 864-880.
|
[4] |
Yang ZF,Poon RT. Vascular changes in hepatocellular carcinoma. Anat Rec, 2008, 291(6): 721-734.
|
[5] |
Bruix J,Sherman M,Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL conference.European Association for the Study of the Liver. J Hepatol, 2001, 35(3): 421-430.
|
[6] |
Frachon S,Gouysse G,Dumortier J, et al. Endothelial cell marker expression in dysplastic lesions of the liver: an immunohistochemical study. J Hepatol, 2001, 34(6): 850-857.
|
[7] |
Ferrara N,Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 1989, 161(2): 851-858.
|
[8] |
Xiao Z,Wang Y,Lu L, et al. Anti-angiogenesis effects of meisoindi-go on chronic myelogenous leukemia in vitro. Leuk Res, 2006, 30(1): 54-59.
|
[9] |
Liu Y,Poon RT,Li Q, et al. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res, 2005, 65(9): 3691-3699.
|
[10] |
Raskopf E,Vogt A,Sauerbruch T, et al. siRNA targeting VEGF in-hibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol, 2008, 49(6): 977-984.
|
[11] |
Moon WS,Park HS,Yu KH, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol, 2006, 37(10): 1324-1332.
|
[12] |
Shen Z,Yang ZF,Gao Y, et al. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res, 2008, 68(2): 404-414.
|
[13] |
Yoshiji H,Kuriyama S,Noguchi R, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut, 2005, 54(12): 1768-1775.
|
[14] |
Zhang ZL,Liu ZS,Sun Q. Expression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of he-patocellular carcinoma. World J Gastroenterol, 2006, 12(26): 4241-4245.
|
[15] |
Kuboki S,Shimizu H,Mitsuhashi N, et al. Angiopoietin-2 levels in the hepatic vein as a useful predictor of tumor invasiveness and progno-sis in human hepatocellular carcinoma. J Gastroenterol Hepatol, 2008, 23(7 Pt 2): e157-e164.
|
[16] |
Mizuno H,Ogura M,Saito Y, et al. Changes in adhesive and migratory characteristics of hepatocellular carcinoma(HCC) cells induced by expression of alpha3betal integrin. Biochim Biophys Acta, 2008, 1780(3): 564-570.
|
[17] |
North S,Moenner M,Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett, 2005, 218(1): 1-14.
|
[18] |
Corpechot C,Barbu V,Wendum D, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogen-esis in experimental cirrhosis. Hepatology, 2002, 35(5): 1010-1021.
|
[19] |
Ankoma-Sey V,Wang Y,Dai Z. Hypoxic stimulation of vascular endothelial growth factor expression in activated rat hepatic stellate cells. Hepatology, 2000, 31(1): 141-148.
|
[20] |
Bråkenhielm E,Cao R,Gao B, et al. Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res, 2004, 94(12): 1579-1588.
|
[21] |
孟立祥,李建生,英卫东,等. TNP-470对人肝癌细胞株HepG2体外形成血管生成拟态的抑制作用.中华实验外科杂志, 2009, 26(10): 1385.
|
[22] |
Bruix J,Sala M,Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology, 2004, 127(5 Suppl 1): S179-S188.
|
[23] |
von Marschall Z,Cramer T,Höcker M, et al. Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut, 2001, 48(1): 87-96.
|
[24] |
Hawighorst H,Knapstein PG,Knopp MV, et al. Uterine cervical carcinoma: comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient surviv-al. Cancer Res, 1998, 58(16): 3598-3602.
|
[25] |
曹玮,王执民,梁志会,等.血管生成抑制剂TNP-470与碘化油混合栓塞肝癌的实验研究.世界华人消化杂志, 2000, 8(6): 629-632.
|